Quest will offer the first FDA-approved blood test to help detect Alzheimer’s-related amyloid pathology in patients with ...

Despite concerns raised by clinicians and ethicists, direct-to-consumer testing for Alzheimer’s disease biomarkers is here, ...

The Lumipulse Alzheimer's blood test is the first of a new generation of tests that may replace brain scans and spinal taps to detect the disease.

The lumipulse blood test brings renewed hope for earlier diagnosis and treatment for millions of people facing the uncertainty of Alzheimer's disease and other dementias.

Quest Diagnostics has signed up to offer a blood test that can help diagnose Alzheimer’s disease, following its FDA clearance earlier this year. | The Lumipulse G blood test measures the ratio between ...

The Lumipulse blood test identifies the presence of amyloid plaques, a hallmark of Alzheimer’s disease that impairs normal brain function.

The FDA has cleared Lumipulse, the first-ever blood test for early Alzheimer's detection, reducing the need for costly and invasive procedures.

The test may make it easier to identify whether people with memory and thinking problems have Alzheimer’s or not.

The Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio is approved for the early detection of amyloid plaques associated with Alzheimer disease in patients aged 55 years and older who are showing ...

The first Alzheimer's blood test cleared by the Food And Drug Administration is poised to change the way doctors diagnose and treat the disease.

The Lumipulse Alzheimer's blood test is the first of a new generation of tests that may replace brain scans and spinal taps to detect the disease.